Editor's Corner



I want to flag the link for our upcoming webinar on economic development issues. On March 1 our panel will look at the way new incentives are being styled to help attract emerging biotech companies and spur development of new clusters.

Also, don't miss my conversation (below) with Dr. Carl Spana, the CEO of Palatin Technologies. Dr. Spana discusses his recent $310 million licensing deal with AstraZeneca and the new opportunities biotech companies can tap in on at an early stage of development. - John Carroll

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.